ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: Results from a randomised, phase II trial

British Journal of Cancer

Volumn 109, Issue 8, 2013, Pages 2096-2105

  Bauman, J E ^a   Austin, M C ^b   Schmidt, R ^b   Kurland, B F ^a,c   Vaezi, A ^a   Hayes, D N ^d   Mendez, E ^b   Parvathaneni, U ^b   Chai, X ^c   Sampath, S ^e   Martins, R G ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e City of Hope ^*  (United States)

Author keywords

biomarker; cisplatin; ERCC1; head and neck cancer; HPV; XPF

Indexed keywords

CISPLATIN; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4F9; MONOCLONAL ANTIBODY 8F1; MONOCLONAL ANTIBODY FL297; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTIBODY SPECIFICITY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUINAZOLINES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84885914044     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.576     Document Type: Article

References (41)

1. Adelstein DJ, Li Y, Adams GL, Wagner Jr. H, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21(1): 92-98.
2. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, KimH, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1): 24-35.
3. Babic A, Loftin IR, Stanislaw S, Wang M, Miller R, Warren SM, Zhang W, Lau A, Miller M, Wu P, Padilla M, Grogan TM, Pestic-Dragovich L, McElhinny AS (2010) The impact of pre-analytical processing on staining quality for H&E, dual hapten, dual color in situ hybridization and fluorescent in situ hybridization assays. Methods 52(4): 287-300.
4. Barnhart HX, Haber M, Song J (2002) Overall concordance correlation coefficient for evaluating agreement among multiple observers. Biometrics 58(4): 1020-1027.
5. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M. European Organization for R, Treatment of Cancer T (2004) Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl JMed 350(19): 1945-1952.
6. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ (2009) Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69(17): 6831-6838.
7. Britten RA, Liu D, Tessier A, Hutchison MJ, Murray D (2000) ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89(5): 453-457.
8. Chiu TJ, Chen CH, Chien CY, Li SH, Tsai HT, Chen YJ (2011) High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area. J Transl Med 9: 31.
9. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK. Radiation Therapy Oncology Group I (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350(19): 1937-1944.
10. Crawford SB, Kosinski AS, Lin HM, Williamson JM, Barnhart HX (2007) Computer programs for the concordance correlation coefficient. Comput Methods Programs Biomed 88(1): 62-74.
11. De Silva IU, McHugh PJ, Clingen PH, Hartley JA (2000) Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20(21): 7980-7990.
12. Fountzilas G, Bamias A, Kalogera-Fountzila A, Karayannopoulou G, Bobos M, Athanassiou E, Kalogeras KT, Tolis C, Tsekeris P, Papakostas P, Vamvouka C, Zaramboukas T, Kosmidis P, Zamboglou N, Misailidou D (2009) Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res 29(2): 529-538.
13. Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour L, Pirker R, Filipits M, Andre F, Solary E, Ponsonnailles F, Robin A, Stoclin A, Dorvault N, Commo F, Adam J, Vanhecke E, Saulnier P, Thomale J, Le Chevalier T, Dunant A, Rousseau V, Le Teuff G, Brambilla E, Soria JC (2013) ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl JMed 368(12): 1101-1110.
14. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guily J, Soria JC, Fouret P (2007) Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancerspecific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 13(13): 3855-3859.
15. Hao D, Lau HY, Eliasziw M, Box A, Diaz R, Klimowicz AC, Shin B, Lees-Miller SP, Magliocco AM (2011) Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. Head & neck 34(6): 785-791.
16. Hayes M, Lan C, Yan J, Xie Y, Gray T, Amirkhan RH, Dowell JE (2011) ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res 31(12): 4135-4139.
17. Henk JM (1997) Controlled trials of synchronous chemotherapy with radiotherapy in head and neck cancer: overview of radiation morbidity. Clin Oncol 9(5): 308-312.
18. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59(8): 1935-1940.
19. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5): 277-300.
20. Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M, Jiang B, Wakely P, Xiao W, Gillison ML (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36(7): 945-954.
21. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K (2008) ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer 99(1): 167-172.
22. Kamangar F, Dores GM, Anderson WF (2006) Patterns of Cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14): 2137-2150.
23. Koh Y, Kim TM, Jeon YK, Kwon TK, Hah JH, Lee SH, Kim DW, Wu HG, Rhee CS, Sung MW, Kim CW, Kim KH, Heo DS (2009) Class III betatubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol 20(8): 1414-1419.
24. Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, Hoang T, FuW, Min L, Lan ZS, Wang F, Mull L, He WW (2012) Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol 12(1): 88.
25. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X, Wallace SG, Austin M, Schmidt R, Hayes DN (2013a) Cisplatinradiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: A randomized phase II trial. J Clin Oncol 31(11): 1415-1421.
26. Martins RG, Parvathaneni U, Bauman JE, Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD, Liao JJ, Mendez E, Futran N, Wang DX, Chai X,Wallace SG, Austin M, Schmidt R, Hayes DN (2013b) Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial. J Clin Oncol 31(11): 1415-1421.
27. Milas L, Milas MM, Mason KA (1999) Combination of taxanes with radiation: Preclinical studies. Semin Radiat Oncol 9(2 Suppl 1): 12-26.
28. Moeller BJ, Yordy JS, Williams MD, Giri U, Raju U, Molkentine DP, Byers LA, Heymach JV, StoryMD, Lee JJ, Sturgis EM,Weber RS, Garden AS, Ang KK, Schwartz DL (2011) DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res 17(7): 2035-2043.
29. Niedernhofer LJ, Bhagwat N, Wood RD (2007) ERCC1 and non-small-cell lung cancer. N Engl J Med 356(24): 2538-2540, author reply 2540-1.
30. Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, Odijk H, Oostendorp R, Ahmad A, van Leeuwen W, Theil AF, VermeulenW, van derHorstGT, Meinecke P, KleijerWJ, Vijg J, JaspersNG, Hoeijmakers JH (2006) A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature 444(7122): 1038-1043.
31. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, Investigators IB (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991.
32. Palom Y, Suresh Kumar G, Tang LQ, Paz MM, Musser SM, Rockwell S, Tomasz M (2002) Relative toxicities of DNA cross-links and monoadducts: new insights from studies of decarbamoyl mitomycin C and mitomycin C. Chem Res Toxicol 15(11): 1398-1406.
33. Pignon JP, le Maitre A, Maillard E, Bourhis J. GroupM-NC (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17 346 patients. Radiother Oncol 92(1): 4-14.
34. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29.
35. Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G (2012) Preliminary indication of survival benefit from ERCC1 and RRM1- tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer 118(9): 2525-2531.
36. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, Mountzios G, Validire P, Domont J, Girard P,Grunenwald D, LeChevalier T, Soria JC (2007) Immunohistochemichal expression of biomarkers: A comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18(6): 1043-1050.
37. Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry- issues concerning methods, utility and semiquantitative assessment II. Histopathology 49(4): 411-424.
38. Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, Komaroff E, Nalysnyk L, Zilberberg MD (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review. Radiother Oncol 66(3): 253-262.
39. Vaezi A, Feldman CH, Niedernhofer LJ (2011a) ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer. Pharmacogenomics Pers Med 4: 47-63.
40. Vaezi A, Wang X, Buch S, Gooding W, Wang L, Seethala RR, Weaver DT, D?Andrea AD, Argiris A, Romkes M, Niedernhofer LJ, Grandis JR (2011b) XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck. Clin Cancer Res 17(16): 5513-5522.
41. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G (2007) DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356(8): 800-808.